Decreased production of vasodilator substances such as nitric oxide (NO) has been
proposed as important in development of pulmonary arterial hypertension (PAH). We …

The pathogenesis of pulmonary arterial hypertension remains undefined. Changes in the
expression and effects mediated by a number of vasoactive factors have been implicated to …

Primary pulmonary hypertension (PPH) is a rare and fatal disease of unknown etiology.
Inflammatory oxidant mechanisms and deficiency in nitric oxide (NO) have been implicated …

Lack of vasodilator substances, such as nitric oxide (NO), has been implicated in the
development of pulmonary hypertension, but the pathogenesis of the disease remains …

Rationale: Decreased nitric oxide (NO) is considered an important pathogenetic mechanism
in pulmonary arterial hypertension (PAH), but clear evidence is lacking. Objectives: We used …

Chronic pulmonary hypertension is a serious complication of a number of chronic lung and
heart diseases. In addition to vasoconstriction, its pathogenesis includes injury to the …

Pulmonary vascular disease can be defined as either a disease affecting the pulmonary
capillaries and pulmonary arterioles, termed pulmonary arterial hypertension, or a disease …

Pulmonary hypertension is a condition characterized by vasoconstriction, vascular cell
proliferation, inflammation, microthrombosis, and vessel wall remodelation. Pulmonary …

Pulmonary hypertension is an uncommon, yet devastating, syndrome with a complex
underlying pathobiology. Hypoxia, inflammation, and increased shear stress appear to be …

Abstract Pulmonary Arterial Hypertension (PAH) is a disease of the pulmonary vasculature
leading to vasoconstriction and remodeling of the pulmonary arteries. The resulting increase …